Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-360-1 | CAS number: 8007-43-0
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- disregarded due to major methodological deficiencies
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: Does not meet important criteria of todays stadard methods (analytical purity of test substance not provided, only 3% test substance evaluated, test substance part of a cosmetic cleansing cream, no information on doses).
Data source
Referenceopen allclose all
- Reference Type:
- secondary source
- Title:
- Final Report on the Safety Assessment of Sorbitan Stearate, Sorbitan Laurate, Sorbitan Sesquioleate, Sorbitan Oleate, Sorbitan Tristearate, Sorbitan Palmitate, and Sorbitan Triolate
- Author:
- Elder, R.L., ed.
- Year:
- 1 985
- Bibliographic source:
- Journal of the American College of Toxicology 4(3): 65-121
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 968
- Report date:
- 1968
Materials and methods
- Principles of method if other than guideline:
- Cosmetic cleansing cream containing 3% of test substance was tested in a patch test after 24 hour exposure. 14 days observation time.
- GLP compliance:
- no
- Test type:
- standard acute method
Test material
- Reference substance name:
- 8007-43-0 [purity: 3%]
- IUPAC Name:
- 8007-43-0 [purity: 3%]
- Details on test material:
- - Name of test material (as cited in study report): sorbitan sesquioleate
- Analytical purity: no data
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- other: albino
- Sex:
- male/female
Administration / exposure
- Type of coverage:
- not specified
- Vehicle:
- not specified
- Duration of exposure:
- 24 hours
- Doses:
- 200 and 300 mg/kg bw (3% of 6800 and 10200 mg/kg bw applied cleansing cream)
- No. of animals per sex per dose:
- 2
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Other examinations performed: clinical signs, dermal effects
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 300 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality observed.
- Clinical signs:
- other: Definite erythema at application site was observed.
- Gross pathology:
- No data
Applicant's summary and conclusion
- Interpretation of results:
- other: inconclusive
- Remarks:
- Criteria used for interpretation of results: EU
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
